News|Articles|August 19, 2024

Neuroprotective Potential of N-Acetylcysteine: Mitigating Cannabis-Induced Neuropsychiatric Risks in Adolescence

Author(s)Erin McEvoy

A new study demonstrates the neuroprotective properties of the supplement N-Acetylcysteine against effects of cannabis exposure in adolescence.

A recently published study (1) found that the antioxidant, N-Acetylcysteine (NAC), could protect adolescent brains from developing anxiety and depressive behaviors caused by sustained exposure to tetrahydrocannabinol (THC). NAC, available as a dietary supplement, has been generally proposed as a treatment for neuropsychiatric conditions due to its ability to regulate neurotransmitter balance, regulate oxidative stress, and more.

As explained in the study, sustained exposure to THC in early adolescence can lead to “neuropsychiatric vulnerability, including mood and anxiety-related symptoms” later in life. In particular, nucleus accumbens (Acb), a common link for signaling pathways related to affective disorders and addiction, is susceptible to alteration by THC. Additionally, developing brains are sensitive to oxidative stress, which cannabis increases. Mood and anxiety disorders are associated with compromised antioxidant responses.

Using rodent models, the researchers tested the effect of THC on adolescent rats and the effects of NAC as an intervention. “We report that adolescent THC induces long-lasting anxiety and depressive-like phenotypes, concomitant with dissociable molecular and neuronal activity alterations in AcbSh vs. AcbC,” the researchers stated. “Remarkably, NAC administration normalized these THC-induced phenotypes while preventing dysregulations in metabolomic biomarkers associated with mood and anxiety-related pathophysiology.”

“Our study provides several novel discoveries linking the impacts of cannabinoid-induced striatal pathophysiology on markers for affective dysregulation which is a concerning risk factor for chronic adolescent cannabis use,” the researchers concluded. “Importantly, the present findings suggest that antioxidant interventions may serve as a potential pharmacotherapeutic approach to the prevention of neurodevelopmental disorders induced by cannabis exposure.”

Reference

  1. De Felice, M., Szkudlarek, HJ., Uzuneser, TC., Rodríguez-Ruiz, M., Sarikahya, MH., Pusparajah, M., Galindo Lazo, JP., Whitehead, SN., Yeung, KKC., Rushlow, WJ., Laviolette, S. The Impacts of Adolescent Cannabinoid Exposure on Striatal Anxiety and Depressive-like Pathophysiology are Prevented by the Antioxidant N-Acetylcysteine. Biological Psychiatry: Global Open Science. 2024, DOI: 10.1016/j.bpsgos.2024.100361

Related to this article

2025 Medical Cannabis Roundup
Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
Image | adobe.stock/Stock Rocket
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
Image | adobe.stock/Maksim Kabakou
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!
Best of the Week: December 12 – December 18, 2025
Our top cannabis news topics this week: President Trump’s executive order on cannabis rescheduling, hemp regulation legislation, NY program using cannabis to reduce opioid use, cannabis genetics and cannabinoid profiles, and the latest cannabis research studies.